Cost-effectiveness assessment of drotrecogin alfa vs standard care in severe sepsis in real practice;Évaluation coût-efficacité de la drotrècogine alfa comparée à la prise en charge conventionnelle dans le traitement du sepsis sévère en pratique réelle

Journal d'Economie Medicale

Volumn 25, Issue 4, 2007, Pages 207-223

  Payet, S ^a   Riou Franca L ^a   Le Lay, K ^a   Vallet, B ^b   Dhainaut, J F ^c   Launois, R ^a  

^a REES   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Bootstrap; Cost effectiveness; Drotrecogin alpha; Observational study; Propensity score

Indexed keywords

EID: 36248991776     PISSN: 02940736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 Mar 8;344(10):699-709.
2. Hartz A, Marsh JL. Methodologic Issues in Observational Studies. Clinical Orthopaedics and Related Research, 2003.
3. Launois R, Cartraud A, Perez V. Evaluation of integrated health delivery systems - example from France. In Preub KJ, Räbiger J, Sommer JH (Eds): Managed Care - Evaluation und Performance-Measurement integrierter Versorfungsmodelle. Schattauer. Stuttgart 2001, Chap. 12, p. 171-190.
4. Launois R, Mègnigbêto AC, Pérez V, Roy M, Camus A, Gailhardou M, Lançon F, Quéniart M. Expérimentation de la prise en charge de l'asthme en réseau de soins coordonnés® bilan de l'expérience RESALIS dans l'Eure, 18 mois avant et 12 mois après intervention. Journal d'Economie Médicale 2002;20(6):333-352.
5. Launois R. L'évaluation socio-économique une discipline entre recherche clinique et études observationnelles. Bull cancer 2003;90(1):97-104.
6. Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD, McNeil BJ. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001 Apr;54(4):387-98.
7. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
8. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998 Oct 15;17(19):2265-81.
9. Yanovitsky I, Zanutto E, Hornik R. Estimating causal effects of public health education campaigns using propensity score methodology. Evaluation and program planning 2005;28:209-220.
10. MayoClinicCollege of Medicine. http://mayoresearch.mayo.edu/mayo/ research/biostat/upload/match.sas
11. Aegerter P, Auvert B, Buonamico G, Sznadjer M, Beauchet A, Guidet B, Le Gall JR, Cub-Réa. Organization and quality control of a clinical database on intensive care medicine in central and suburban Paris. Rev Epidemiol Sante Publique 1998;46(3):226-37.
12. Sznajder M, Aegerter P, Launois R, Merliere Y, Guidet B, CubRea. A cost-effectiveness analysis of stays in intensive care units. Intensive Care Med 2001 Jan;27(1):146-53.
13. Launois R. Un coût, des coûts, quels coûts ? Journal d'Economie Médicale 1999;17(1):77-82.
14. Launois R, Vergnenègre A, Garrigues B. Notions et mesure des coûts en fonction de la perspective choisie. Bull Cancer 2003;90(11):946-54 repris dans Guide méthodologique pour l'évaluation des actions de santé, recommandations méthodologiques - CES Paris 2003. Annexe I.
15. Riou-França L, Launois R, Le Lay K, Aegerter P, Bouhassira M, Meshaka P, Guidet B. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure. Int J of technology assessment in health care 2006;22(1):101-108.
16. Site de l'INSEE. http://www.insee.fr/fr/indicateur/achatfranc.htm
17. Launois R, Payet S, Riou-França L et al. L'évaluation des technologies de santé : les protocoles de deuxième génération. Journal d'Économie Médicale 2006;24:213-228.
18. Launois R. La recherche de l'efficience : un impératif déontologique. Médecine Sciences (NS) août 1990:25-30.
19. Launois R. Qu'est-ce que la régulation médicalisée. Journal d'économie médicale 1994;12:63-74.
20. Launois R, Lhoste F. Quelle place pour l'évaluation économique en matière de politique de santé? Journal d'Economie Médicale 2002;20(2): 128-135.
21. Site de l'Institut National des Etudes Démographiques (INED). http://www.ined.fr/population-en-chiffres/france/index.html.
22. Quartin AA, Schrein RM, Kett DH, Peduzzi PN. Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Co-operative Studies Group. JAMA 1997 Apr 2;277(13):1058-63.
23. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002;11:415-430.
24. Vant Hout BA, Al MJ, Gordon GS, Rutten FFH. Costs, effects and C/E-ratios alongside a clinical trial. Health Economics 1994;3:309-319.
25. World Health Organization. Making choices in health: WHO guide to cost effectiveness analysis. 2003. Edited by T Tan-Torres Edejer, R Baltussen, T Adam, R Hutubessy, A Acharya, DB Evans, CJL Murray.
26. Hartz A, Marsh JL. Methodologic Issues in Observational Studies. Clinical Orthopaedics and Related Research, 2003.
27. Klungel OH, Martens EP, Psaty BM, Grobbee DE, Sullivan SD, Stricker BH, Leufkens HGM, de Boer A. Methods to assess intended effects of drug treatment in observational studies are reviewed. Journal of Clinical Epidemiology 2004;57:1223-1231.
28. Guidet B, Misset B. PMSI et réanimation. Collection d'anesthésie, de réanimation et d'urgences, 2000, Editions Masson.
29. Briggs AH, O'Brien BJ. The death of cost-minimisation analysis? Health Econ 2001;10:179-184.
30. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004 May;13(5):437-52.
31. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000 Jul-Sep;20(3):332-42.
32. Neilson AR, Burchardi H, Chinn C, Clouth J, Schneider H, Angus D. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J Crit Care.